Prognostic value of F-18-fluorodeoxyglucose PET/computed tomography metabolic parameters measured in the primary tumor and suspicious lymph nodes before neoadjuvant therapy in patients with esophageal carcinoma

Nenhuma Miniatura disponível
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
Citação
NUCLEAR MEDICINE COMMUNICATIONS, v.42, n.4, p.437-443, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background F-18-fluorodeoxyglucose PET/computed tomography (F-18-FDG PET/CT) metabolic parameters are prognostic indicators in several neoplasms. This study aimed to evaluate the prognostic value of the maximum and average standardized uptake value (SUVmax and SUVavg), metabolic tumor value (MTV), and total lesion glycolysis (TLG) measured in the primary tumor and suspicious lymph nodes preneoadjuvant therapy in patients submitted to surgical resection for esophageal cancer. Methods A cohort of 113 patients with esophageal cancer who performed F-18-FDG PET/CT preneoadjuvant therapy was assessed. The association of the SUV, MTV, and TLG measured in the primary tumor and in the suspicious lymph nodes with the overall survival was assessed. It was also analyzed other potentially confounding variables such as age, sex, clinical stage, and histologic subtype. The analyses were performed using Kaplan-Meier curve, log-rank test, and Cox regression. Results The univariate analyses showed that the MTV and TLG in the primary tumor, the SUV in the suspicious lymph nodes, the age, the histologic subtype, and the clinical stage were associated with survival after surgery (P <= 0.05). In the Cox regression multivariate analyses, all variables identified in the univariate analyses but the clinical stage were associated with survival after surgery (P <= 0.05). Conclusion In esophageal cancer patients, some of the F-18-FDG PET/CT metabolic parameters measured in the primary tumor and in the suspicious lymph nodes before the neoadjuvant therapy are independent indicators of overall survival and appear to be more important than the clinical stage in the prognostic definition of this group of patients.
Palavras-chave
esophageal neoplasms, neoadjuvant therapy, nuclear medicine, PET
URI
https://observatorio.fm.usp.br/handle/OPI/40679
Referências
  1. BROWN RS, 1995, J NUCL MED, V36, P1854
  2. Butof R, 2015, J NUCL MED, V56, P1150, DOI 10.2967/jnumed.115.155309
  3. Cacicedo J, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160217
  4. Castelli J, 2019, EUR J NUCL MED MOL I, V46, P638, DOI 10.1007/s00259-018-4134-9
  5. Chang S, 2016, CANCER BIOTHER RADIO, V31, P1, DOI 10.1089/cbr.2015.1932
  6. Chen PJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07044-4
  7. Chung HH, 2012, ANN SURG ONCOL, V19, P1966, DOI 10.1245/s10434-011-2153-x
  8. Damhuis Ronald A M, 2005, World J Surg Oncol, V3, P71, DOI 10.1186/1477-7819-3-71
  9. Dibble EH, 2012, J NUCL MED, V53, P709, DOI 10.2967/jnumed.111.099531
  10. Elimova E, 2015, EUR J CANCER, V51, P2545, DOI 10.1016/j.ejca.2015.07.044
  11. Hatt M, 2011, EUR J NUCL MED MOL I, V38, P1595, DOI 10.1007/s00259-011-1834-9
  12. Hatt M, 2011, EUR J NUCL MED MOL I, V38, P1191, DOI 10.1007/s00259-011-1755-7
  13. Hofheinz F, 2019, EUR J NUCL MED MOL I, V46, P1485, DOI 10.1007/s00259-019-04307-6
  14. Hong JH, 2016, J KOREAN MED SCI, V31, P39, DOI 10.3346/jkms.2016.31.1.39
  15. Hyun SH, 2010, ANN SURG ONCOL, V17, P115, DOI 10.1245/s10434-009-0719-7
  16. Jayachandran P, 2012, INT J RADIAT ONCOL, V84, P471, DOI 10.1016/j.ijrobp.2011.12.029
  17. Jin F, 2018, CLIN LUNG CANCER, V19, pE101, DOI 10.1016/j.cllc.2017.06.006
  18. Kelsen DP, 1998, NEW ENGL J MED, V339, P1979, DOI 10.1056/NEJM199812313392704
  19. LAUSEN B, 1992, BIOMETRICS, V48, P73, DOI 10.2307/2532740
  20. Lee HY, 2010, ANN SURG ONCOL, V17, P2787, DOI 10.1245/s10434-010-1107-z
  21. Lemarignier C, 2014, EUR J NUCL MED MOL I, V41, P2008, DOI 10.1007/s00259-014-2839-y
  22. Li YM, 2015, INT J CLIN EXP MED, V8, P10947
  23. Liao SR, 2012, EUR J NUCL MED MOL I, V39, P27, DOI 10.1007/s00259-011-1934-6
  24. Lim R, 2012, J NUCL MED, V53, P1506, DOI 10.2967/jnumed.111.101402
  25. Lin CH, 2020, CANCERS, V12, DOI 10.3390/cancers12030607
  26. Lu CH, 2018, ASIAN J SURG, V41, P333, DOI 10.1016/j.asjsur.2017.02.008
  27. Mac Manus M, 2008, INT J RADIAT ONCOL, V72, P1298, DOI 10.1016/j.ijrobp.2008.08.022
  28. Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
  29. Meyers BF, 2007, J THORAC CARDIOV SUR, V133, P738, DOI 10.1016/j.jtcvs.2006.09.079
  30. Moon SH, 2013, HEAD NECK-J SCI SPEC, V35, P15, DOI 10.1002/hed.22904
  31. Mota FC, 2018, INT J SURG, V54, P176, DOI 10.1016/j.ijsu.2018.04.053
  32. Odawara S, 2018, EUR J RADIOL, V101, P65, DOI 10.1016/j.ejrad.2018.02.009
  33. Reynolds JV, 2007, ANN SURG, V245, P707, DOI 10.1097/01.sla.0000254367.15810.38
  34. Rice TW, 2017, ANN CARDIOTHORAC SUR, V6, P119, DOI 10.21037/acs.2017.03.14
  35. Schwartz DL, 2015, INT J RADIAT ONCOL, V91, P721, DOI 10.1016/j.ijrobp.2014.12.023
  36. Son SH, 2018, CLIN NUCL MED, V43, pE296, DOI 10.1097/RLU.0000000000002188
  37. Soydal C, 2014, MOL IMAGING RADIONUC, V23, P12, DOI 10.4274/Mirt.07379
  38. van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088
  39. Vlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108
  40. Yap WK, 2017, DIS ESOPHAGUS, V30, DOI 10.1093/dote/dox021
  41. Yap WK, 2018, EUR J NUCL MED MOL I, V45, P689, DOI 10.1007/s00259-017-3901-3
  42. Zhu WY, 2018, ONCOTARGETS THER, V11, P4345, DOI 10.2147/OTT.S160456

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Carregar mais